Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Voyager Therapeutics today and set a price target of $18.00. The company’s shares closed yesterday at $4.68.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Olson is a 4-star analyst with an average return of 7.4% and a 41.24% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Ionis Pharmaceuticals, and Nektar Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Voyager Therapeutics with a $16.38 average price target, implying a 250.00% upside from current levels. In a report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.

VYGR market cap is currently $259.6M and has a P/E ratio of -2.53.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year. Most recently, in August 2025, Toby Ferguson, the CMO of VYGR sold 19,000.00 shares for a total of $70,870.00.